CLEVELAND, Nov. 9 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. , announced today that it has entered contract negotiations with the Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) with respect to Company's proposal submitted in response to the DTRA's Broad Agency Announcement (BAA) DTRA1-06-CBM-BAA.
Cleveland BioLabs submitted a proposal for a collaborative project with the Armed Forces Research Radiobiology Institute to complete development of radiation protectors in response to the Radiological Countermeasures research area outlined by the BAA. The Company has been identified as an "apparent successful offeror" by the DTRA and negotiations are in progress.
According to the BAA, "The full range of flexible acquisition and acquisition-related statutory authority arrangements available to DTRA are possible results from this announcement, including but not limited to Procurement Contracts."
Cleveland BioLabs President and Chief Executive Officer, Michael Fonstein, Ph.D., commented, "Our participation in this program would be a significant milestone for the Company. A contract resulting from this program would support further development of our line of radioprotectant drugs, as well as establish a path for procurement with the DoD."
Protectan CBLB502, the Company's leading radioprotectant molecule, has demonstrated its outstanding efficacy in a recent study when it rescued more than 70% of lethally irradiated primates and substantially delayed death for those that died. CBLB502 is undergoing an accelerated development program under the FDA two-animal rule, which requires the Company to show efficacy in two animal species (including primates) and only safety in humans.
The BAA follows the approval of the Under Secretary of Defense, Acquisition, Technology and Logistics for an "Implementation Plan for the Management of the Department of Defense Chemical and Biological Defense Program (CBDP)." The plan provides implementation procedures and defines the roles and the responsibilities for CBDP management, including planning, programming, budgeting and execution of Chemical/Biological/Radiological/Nuclear (CBRN) defense research, development and acquisition.
The DoD implements a vigorous medical research and development program in chemical, biological and radiological defense with the goal of protecting the warfighter from the ramifications of such warfare agents. The CBDP seeks to develop counter-measures that can be brought into acquisition and fielded worldwide.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."
The Global Consulting Group
T: (646) 284-9439
Cleveland BioLabs, Inc.